Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment | Oncology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Reilly  CM, Bruner  DW, Mitchell  SA,  et al.  A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment.  Support Care Cancer. 2013;21(6):1525-1550.PubMedGoogle ScholarCrossref
Pakhomov  SV, Jacobsen  SJ, Chute  CG, Roger  VL.  Agreement between patient-reported symptoms and their documentation in the medical record.  Am J Manag Care. 2008;14(8):530-539.PubMedGoogle Scholar
Kotronoulas  G, Kearney  N, Maguire  R,  et al.  What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? a systematic review of controlled trials.  J Clin Oncol. 2014;32(14):1480-1501.PubMedGoogle ScholarCrossref
Basch  E, Deal  AM, Kris  MG,  et al.  Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial.  J Clin Oncol. 2016;34(6):557-565.PubMedGoogle ScholarCrossref
Research Letter
July 11, 2017

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

Author Affiliations
  • 1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
  • 2Associate Editor, JAMA
  • 3Memorial Sloan Kettering Cancer Center, New York, New York
  • 4Mayo Clinic, Scottsdale, Arizona
  • 5American Society of Clinical Oncology, Alexandria, Virginia
  • 6Dana-Farber/Harvard Cancer Center, Boston, Massachusetts
JAMA. 2017;318(2):197-198. doi:10.1001/jama.2017.7156

Symptoms are common among patients receiving treatment for advanced cancers,1 yet are undetected by clinicians up to half the time.2 There is growing interest in integrating electronic patient-reported outcomes (PROs) into routine oncology practice for symptom monitoring, but evidence demonstrating clinical benefit has been limited.3

We assessed overall survival associated with electronic patient-reported symptom monitoring vs usual care based on follow-up from a randomized clinical trial.4

The study was approved by the Memorial Sloan Kettering institutional review board and written informed consent was obtained from participants. Consecutive patients initiating routine chemotherapy for metastatic solid tumors at Memorial Sloan Kettering Cancer Center in New York between September 2007 and January 2011 were invited to participate in a randomized clinical trial. Participants were randomly assigned either to the usual care group or to the PRO group, in which patients provided self-report of 12 common symptoms from the National Cancer Institute’s Common Terminology Criteria for Adverse Events at and between visits via a web-based PRO questionnaire platform. Participation was continuous until cessation of cancer treatment, voluntary withdrawal from the trial, transition to hospice care, or death.